Previous studies have shown that DDX52 expression is downregulated by activin-induced inhibition of the proliferation of prostate cancer cells and is associated with lung cancer [12,13]; however, the clinical and biological functions of DDX52 in MM are unknown. Here, DDX52 is linked to prostate carcinoma.